FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Jun. 13, 2018--
MEDNAX,
Inc. (NYSE:MD), the national health solutions partner specializing
in anesthesiology, neonatology, maternal-fetal medicine, other pediatric
services, radiology and management services, is pleased to
announce that it has partnered with Pacira Pharmaceuticals, Inc.
(NASDAQ:PCRX) to address the ongoing use of opioids during and after
cesarean surgery by launching a national collaborative aimed at
addressing the Quadruple Aim through the implementation of an Enhanced
Recovery after Cesarean Surgery (ERACS™) program. The collaborative will
be multi-disciplinary in nature, engaging the expertise of
maternal-fetal medicine physicians, anesthesiologists, obstetricians and
perioperative nurses to improve the patient experience as well as
maternal and infant health, reduce the total cost of care and enhance
provider satisfaction.
The ERACS™ program will encompass comprehensive educational and clinical
implementation pathways. The overarching goals will be to educate
clinical teams, shorten the length of postoperative hospital stays,
reduce the use of opioid analgesics and improve postoperative pain
control. In addition, MEDNAX and Pacira will monitor a series of
clinical quality, safety and value-based performance indicators
including: reduced serious maternal and infant morbidity, reduced
postoperative nausea and vomiting, lower rate of surgical site
infections, lower rate of return to the operating room, lower rate of
readmission to the hospital and lower total cost of care.
“Enhanced Recovery After Surgery (ERAS) service line implementations
have been shown to repeatedly improve the quality of care while at the
same time lowering the cost of care,” Dr. Michael Murphy, Chief Medical
Officer, Anesthesiology and Adult Critical Care Services, MEDNAX. “The
same can be surmised for the elective cesarean surgeries. Lessons
learned by MEDNAX practices following a series of ERAS implementations
in multiple practices will assist in assuring similar results for this
ERACS™ service line implementation.”
“We are excited by the potential of this new program to improve outcomes
for women who need cesarean delivery,” said Dr. Andrew Combs, Ph.D.,
MEDNAX-affiliated maternal-fetal medicine specialist. “ERAS programs
have proven to be successful in other types of surgery, including
colorectal, cancer, head-and-neck, urologic and bariatric surgery. These
programs are usually a win-win, producing better outcomes for patients,
reduced resource utilization for hospitals and lower costs for health
plans. With this new collaborative, we will bring ERAS principles to
pregnant women and their newborns.”
“We look forward to joining forces with MEDNAX on this collaborative to
decrease postsurgical reliance on opioids, and ultimately improve
patient care and the recovery experience for both mothers undergoing
cesarean deliveries and their newborn babies,” said Dave Stack, Chairman
and Chief Executive Officer of Pacira Pharmaceuticals. “We are hopeful
that the launch of this ERACS™ program focused on reducing opioid use
through the implementation of effective, non-opioid options will serve
as a guiding model for healthcare facilities providing both maternal and
fetal specialty services.”
ABOUT MEDNAX
MEDNAX, Inc. is a national health solutions partner based in Sunrise,
Fla. comprised of the nation's leading providers of physician services.
Physicians and advanced practitioners practicing as part of MEDNAX are
reshaping the delivery of care within their specialties and
subspecialties, using evidence-based tools, continuous quality
initiatives, clinical research and telemedicine to enhance patient
outcomes and provide high-quality, cost-effective care. The Company was
founded in 1979, and today, through its affiliated professional
corporations, MEDNAX provides services through a network of
approximately 4,100 physicians in all 50 states and Puerto Rico. In
addition to its national physician network, MEDNAX provides services to
healthcare facilities and physicians in over 40 states through two
complementary businesses, consisting of a revenue cycle management
company and a consulting services company. Additional information is
available at www.mednax.com.
ABOUT PACIRA
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical
company dedicated to advancing and improving postsurgical outcomes for
acute care practitioners and their patients. The company's flagship
product, EXPAREL® (bupivacaine liposome injectable suspension) was
commercially launched in the United States in April 2012. EXPAREL
utilizes DepoFoam®, a unique and proprietary product delivery technology
that encapsulates drugs without altering their molecular structure, and
releases them over a desired period of time. To learn more about Pacira,
including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180613005166/en/
Source: MEDNAX, Inc.
MEDNAX, Inc.
Jennifer Gutierrez, 954-384-0175 ext. 5684
Corporate
Communications Specialist
jennifer_gutierrez@mednax.com